• Schering-Plough Beats Earnings Forecasts By Wide Margin Thursday, 19 Apr 2007 | 11:00 AM ET

    Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.

  • Wyeth Results Up on Growing Vaccine Revenues Thursday, 19 Apr 2007 | 9:29 AM ET

    Wyeth said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.

  • Merck Profit Beats Estimates As Sales of New Drugs Jump Thursday, 19 Apr 2007 | 9:00 AM ET

    Merck  said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.

  • Top Name Breaks $3M Mark In Challenge! Thursday, 19 Apr 2007 | 7:08 AM ET

    Good morning all. Serge Amelyan maintains his lead for the second day running, and Parker Robinson holds 2nd place--as both gain substantially with the top trade of the day on Linear Technology. It was was up 12.20% Wednesday on strong earnings. AND Serge is the first contestant to break the $3M mark with a total portfolio value of $3,236,223.05 up $351,671.04 from Tuesday's total on the sale of Linear Technology.

  • Gilead Sciences Reports Quarterly Earnings Growth of 55% Wednesday, 18 Apr 2007 | 6:04 PM ET

    Gilead Sciences said on Wednesday its first-quarter profit rose 55% amid higher sales of its drugs for HIV, the virus that causes AIDS.

  • Abbott Profit Declines 19% As Charges Offset Higher Sales Wednesday, 18 Apr 2007 | 11:49 AM ET

    Abbott Laboratories said on Wednesday its first-quarter earnings fell 19% as charges related to acquisitions and cost-cutting offset sharply higher sales of its prescription drugs and medical devices. 

  • Mishlove: Contest Stock Picks For Wednesday Wednesday, 18 Apr 2007 | 11:39 AM ET

    Hey folks--we have  guest blogger Jeff Mishlove's contest picks for the day. Let's get right to his comments: Now that the Tuesday results are in, I see that my top recommendation for Monday had a significant price gain. That was Adtran, Inc., which rose 6.16%. This stock had a lot going for it: it was favored by hedge funds and professional investors; it was approaching its 52-week high; a significant amount of stock was controlled by short sellers..

  • Roche First-Quarter Sales up 16%, Raises Outlook Wednesday, 18 Apr 2007 | 2:25 AM ET

    Fast-selling cancer drugs boosted first-quarter sales at Roche Holding by 16% to 11.4 billion Swiss francs ($9.41 billion), the Swiss drugmaker said, raising its outlook for the full year.

  • Choice Vs. Savings: Two Views On Senate Medicare Bill Tuesday, 17 Apr 2007 | 4:06 PM ET

    Should the government be allowed to negotiate Medicare drug prices? Two health-policy experts joined "Power Lunch" to debate whether Federal influence will damage the free market -- or if the current ban on government negotiations hurts the consumer more.

  • Glaxo, Merck Maneuver for Position in HPV Drug Market Tuesday, 17 Apr 2007 | 3:41 PM ET

    Merck and GlaxoSmithKline both released news about their respective treatments for human papillomavirus Tuesday, leaving them "duking it out over what's expected to be the multi-billion dollar HPV cervical cancer vaccine market," reported CNBC's Mike Huckman.

  • A Sense about Stents Tuesday, 17 Apr 2007 | 2:55 PM ET

    Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs  have come under increasing scrutiny over safety.

  • Guest Blogger Sykes: My Picks For the Week Tuesday, 17 Apr 2007 | 1:01 PM ET

    Blogger Timothy Sykes is back with his contest picks. Here's his post: I hope everyone tuned in Friday to witness me becoming the first guest to bring female models on CNBC to show off the beauty of stock charts. The audience and the other studio guests loved it so hopefully I’ve started a new trend. We’ll see…This week’s picks are (in order of importance)...

  • Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.

  • How To Win: More Stock Picks From Analysts Monday, 16 Apr 2007 | 2:37 PM ET

    We have more video from Friday night's contest program, "How To Win." Specifically, more stock picks from our guest analysts. One of them, Timothy Sykes, who is also a guest blogger, loves the charts as you'll hear him explain. He also explains, his picks could have an upside, as well as a down side. So it's buyer beware for sure (fyi--it's that way with all the picks!).

  • Pharmaceutical maker Shire said Monday that its shareholders approved the proposed acquisition of New River Pharmaceuticals.

  • Lilly Tops Estimates, Boosts Guidance Monday, 16 Apr 2007 | 10:39 AM ET

    Drug maker Eli Lilly reported first-quarter earnings and sales ahead of market expectations Monday and also boosted guidance for the year, thanks to strong sales of drugs for schizophrenia and depression.

  • Update: Contest Stock Movers And Shakers Monday, 16 Apr 2007 | 9:56 AM ET

    Here's our look at contest stocks from Thursday's close to Friday's close. Old stand by Freemont General brought owners/sellers some new gains. The most active and widely held stocks remained pretty much the same as they have been. One of the best performers Cott, was up on consolidation news involving Cadbury. Here's the breakdown:

  • John Lechleiter President and Chief Operating Officer of Eli Lilly, told CNBC’s “Squawk Box” that sales of Zyprexa, a drug used to treat schizophrenia, are strong. “We continue to be very bullish about Zyprexa,” Lechleiter said Monday. “We saw 6% sales growth in the U.S. this quarter. We had 14% sales growth internationally.”

  • Game Plan Friday, 13 Apr 2007 | 8:10 PM ET

    It’s Friday, and that means it’s time to huddle up for Cramer’s plays for next week. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Lucky Friday the 13th: As I’ve often detailed, there are many moving parts to getting breaking news on the air. "Friday the 13th" is the last day one might think the stars would decide to align to our benefit, but they did. Beverage maker Cott had been the subject of speculation all day, focusing on a possible merger with Cadbury Schweppes. It was halted before the New York Stock Exchange open for “news pending,” which, of course, only served to fuel that speculation. ...